Histone deacetylase activity limits the response to EZH2 inhibition-based therapy in epithelioid sarcoma and is targetable by epigenetic combination
This study demonstrates that histone deacetylase (HDAC) activity limits the efficacy of EZH2 inhibitor-based therapy in epithelioid sarcoma by preventing chromatin remodeling, but this resistance can be overcome through a rational combination strategy involving HDAC inhibition.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Cancer is often a disease of broken switches inside the cell. In healthy cells, a complex system of chemical tags acts like a dimmer switch for the genes that tell the cell when to grow and when to stop. One specific type of tag, called a methyl group, acts as a heavy lock, keeping growth genes turned off. Another type of tag, an acetyl group, acts as a key that unlocks those genes, allowing them to turn on. In a rare and aggressive form of soft tissue cancer called epithelioid sarcoma, a crucial part of the cell's machinery that normally removes the "lock" is missing. Without this part, the cell relies entirely on a different protein, known as EZH2, to keep the growth genes locked down. Scientists have developed drugs to block this EZH2 protein, hoping to unlock the genes and stop the cancer. However, these drugs work for only a small fraction of patients, leaving researchers to wonder why the treatment fails in so many cases.
A team of researchers set out to solve this mystery by growing tumors from real patients inside mice, creating a living laboratory to test how these cancers react to treatment. They focused on two specific types of epithelioid sarcoma that behaved very differently. One tumor model responded well to a combination of the EZH2-blocking drug and a standard chemotherapy agent called doxorubicin, shrinking significantly before eventually growing back. The second tumor model, however, refused to shrink at all, no matter how the drugs were administered. By studying these two models side by side, the scientists discovered that the difference lay in how the cancer cells managed their internal "dimmer switches." In the responsive tumor, blocking EZH2 successfully removed the locks on the genes, allowing them to turn on. But in the resistant tumor, another set of enzymes, known as histone deacetylases, immediately stepped in to re-lock the genes, effectively canceling out the effect of the EZH2 drug. These deacetylases act like a rapid-response repair crew that undoes the work of the EZH2 inhibitor, keeping the cancer genes silenced and the tumor alive.
To test if this repair crew was the true cause of the resistance, the researchers added a third drug to the mix, one designed to stop the deacetylases from working. When they combined the EZH2 blocker, the chemotherapy, and this new deacetylase inhibitor, the resistant tumor finally began to respond. The chemical locks were removed, the genes turned on, and the cancer cells started to die. This finding suggests that the failure of EZH2 drugs in some patients is not because the target is wrong, but because the cancer has a backup system that quickly reverses the drug's effect. The study also looked at a different type of cancer with the same missing machinery, called malignant rhabdoid tumor, and found that this same backup system was active there as well, suggesting the solution might work across a broader range of diseases.
The researchers also observed that the cancer cells in the resistant model had a more aggressive, mobile shape and moved more easily through tissue, characteristics often linked to harder-to-treat cancers. They found that the resistant tumors were busy reorganizing their internal structure in ways that the responsive tumors were not, essentially fortifying themselves against the drug attack. By blocking the deacetylase enzymes, the team was able to break down these defenses and force the cancer cells to undergo programmed death. While the study was conducted in the lab and in mice, it provides a clear biological reason for why some patients do not respond to current treatments and points toward a specific strategy to fix it. The work indicates that combining drugs to block both the EZH2 protein and the deacetylase repair crew could be a powerful way to overcome resistance, offering a new path forward for patients who currently have very few options.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.